Zenas BioPharma, Inc. (ZBIO)
Nasdaq: ZBIO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2022
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 16, 2026 | Mar 11, 2025 | · |
| Revenue | 10,000 | 5,000 | 50,000 |
| Research and development | 168,063 | 139,139 | 60,033 |
| General and administrative | 53,322 | 29,749 | 17,114 |
| Total operating expenses | 393,057 | 168,888 | 87,147 |
| Operating income | -383,057 | -163,888 | -37,147 |
| Interest expense | 7,327 | · | · |
| Interest and investment income | 12,151 | 7,973 | · |
| Other income (expense), net | 417 | 202r | 624 |
| Total non-operating income (expense) | 5,241 | 7,329 | 324 |
| Income before income taxes | -377,816 | -156,559 | -36,823 |
| Income tax expense | -79 | 429 | 301 |
| Net income | -377,737 | -156,988 | -37,124 |
| Earnings per share, basic | -8.44 | -11.89 | -24.25 |
| Earnings per share, diluted | -8.44 | -11.89 | -24.25 |
| Weighted average shares, basic | 44,730,052 | 13,198,960 | 1,531,178 |
| Weighted average shares, diluted | 44,730,052 | 13,198,960 | 1,531,178 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding